SEC Tracker
Get the app

Coherus Oncology CHRS

Coherus Oncology Q2 FY24: net loss $12.9M; diluted EPS −$0.11

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Coherus Oncology reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$12.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.11No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$159.2MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations$59.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Coherus Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Entera Bio ENTX public float $85M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025